



Date: 21 August 2023

То	То
BSE Limited	National Stock Exchange of India Limited
Phiroze Jeejeebhoy Towers	Exchange Plaza
Dalal Street	Bandra Kurla Complex
Mumbai- 400001	Bandra (E)
	Mumbai-400051
Security Code: 540596	Symbol: ERIS

SUBJECT: INTIMATION UNDER REGULATION 30 AND OTHER APPLICABLE REGULATIONS OF SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 (SEBI LODR, 2015)

Dear Sir/Madam,

We would like to inform that the Company has entered into Term Loan Agreement dated 21 August 2023 to avail the Rupee Term Loan facility amounting to ₹120.82 Crores (Rupees One Hundred Twenty Crores Eighty-Two Lakhs Only) from Citi Bank N.A. ("**Bank**"). However, the consolidated net debt of the Company is not expected to be altered due to this development as an equivalent amount is expected to be paid by EOHPL to Citi bank towards repayments of outstanding loans over the next fortnight.

In accordance with requirement of regulations 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Para B (5) of Part A of Schedule III and SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, details attached herein shall be taken on record.

Thanking You,

For Eris Lifesciences Limited



Milind Talegaonkar Company Secretary & Compliance Officer Membership No: A26493 Encl: As above

Registered & Corporate Office:





Agreements (viz. loan agreement(s) or any other agreement(s) which are binding and not in normal course of business, revision(s) or amendment(s) and termination(s) thereof:

Sr. No.	Particulars	Details
1.	name(s) of parties with whom the agreement is	Citi Bank N.A. ("Bank") and Eris Lifesciences
	entered	Limited (" Company ")
2.	purpose of entering into the agreement	Availing Rupee Term Loan to acquire
		dermatology trademarks from Eris Oaknet
		Healthcare Private Limited ("EOHPL"), wholly
		owned subsidiary, as intimated by the Company
		on July 03, 2023.
		The funds so acquired by EOHPL from the
		Company are to be reportedly used for the
		repayment/closure of Citi bank loans availed by
		EOHPL which were secured through the
		corporate guarantee of the Company as reported
		on January 17, 2023.
3.	size of agreement	₹120.82 Crores (Rupees One Hundred Twenty
		Crores Eighty-Two Lakhs Only)
4.	shareholding, if any, in the entity with whom the	NIL
	agreement is executed	
5.	significant terms of the agreement (in brief) special	The Bank shall have a pari-passu charge along
	rights like right to appoint directors, first right to	with HDFC Bank on the trademarks acquired
	share subscription in case of issuance of shares,	from Eris Oaknet Healthcare Private Limited.
	right to restrict any change in capital structure etc.	
6.	whether, the said parties are related to	NA
	promoter/promoter group/ group companies in any	
	manner. If yes, nature of relationship	
7.	whether the transaction would fall within related	NA
	party transactions? If yes, whether the same is	
	done at "arm's length"	
8.	in case of issuance of shares to the parties, details	NA
	of issue price, class of shares issued	
9.	in case of loan agreements:	

Registered & Corporate Office:





	details of lender/borrower,	Citi Bank N.A.
	nature of the loan,	Rupee Term Loan
	 total amount of loan granted/taken, 	₹120.82 Crores (Rupees One Hundred Twenty Crores Eighty-Two Lakhs Only)
	 total amount outstanding, 	NIL
	date of execution of the loan agreement/sanction letter	The loan agreement was executed on the date of this intimation
	details of the security provided to the lenders / by the borrowers for such loan or in case outstanding loans lent to a party or borrowed from a party become material on a cumulative basis;	The Bank shall have a pari-passu charge along with HDFC Bank on the trademarks acquired from Eris Oaknet Healthcare Private Limited.
10.	any other disclosures related to such agreements, viz., details of nominee on the board of directors of the listed entity, potential conflict of interest arising out of such agreements, etc.	NA
11.	 in case of termination or amendment of agreement, listed entity shall disclose additional details to the stock exchange(s): name of parties to the agreement; nature of the agreement; date of execution of the agreement; details of amendment and impact thereof or reasons of termination and impact thereof. 	NA